IMR Press / EJGO / Volume 40 / Issue 1 / DOI: 10.12892/ejgo4270.2019
Open Access Original Research
Risk of cervical cancer and squamous intraepithelial lesions according to human papillomavirus high-risk serotypes detected by qualitative real-time in vitro PCR
Show Less
1 Fetal Medicine Research Centre, BCNatal | Barcelona Centre for Maternal Fetal and Neonatal Medicine Hospital Clinic of Barcelona, Barcelona University, Barcelona, Spain
2 Colposcopy Department, Adolfo Lopez Mateos Hospital, ISSSTE, Mexico City, Mexico
Eur. J. Gynaecol. Oncol. 2019 , 40(1), 19–22;
Published: 10 February 2019

Purpose of investigation: To establish the relationship between high-risk human papillomavirus (hrHPV) serotypes and the odds of developing cervical intraepithelial lesions. Material and Methods: Retrospective cohort study using altered cervical cytology results and hrHPV test obtained by PCR. Groups were divided according to low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL) and squamous cervical cancer (SCC) results, while hrHPV was divided according to polymerase chain reaction (PCR) results in “other HR-HPV, HPV-16, and HPV-18. Logistic regression analysis was performed to estimate the odds of each hrHPV serotype in developing squamous intraepithelial lesions or SCC. Results: A total of 252 samples were analysed, mean age was 42 ± 12.65 years. Prevalence of hrHPV infection was 60% (n=152). “Other HR-HPV” group was the most common infection in our population (39%); nonetheless, there were no increased odds for any HPV group and the risk for developing LSIL. The odds for HSIL were 4.58 and 7 for “other HR-HPV” and HPV-16, respectively. Odds for SCC were 11.29 and 7.35 for HPV-18 and HPV-16. There were no significant odds in HPV-18 for HSIL and “other HR-HPV” SCC. Conclusion: The present authors found a greater prevalence for “other HR-HPV” group in this population. Nonetheless, HPV-16 and HPV-18 contribute the highest probability of developing HSIL and SCC.

Human papillomavirus
Cervical carcinoma
Figure 1.
Back to top